Document Detail

Initial use of once-monthly administration of C.E.R.A. is effective and safe in correcting renal anemia in non-dialysis patients: the MERCUR trial.
MedLine Citation:
PMID:  22874107     Owner:  NLM     Status:  In-Data-Review    
Background: Continuous erythropoietin receptor activator (C.E.R.A.) is routinely given once every 2 weeks to correct hemoglobin (Hb) level, but monthly use is recommended in the maintenance phase. Patients and methods: In an open-label, single- arm, multicenter trial, 184 ESA-naïve non-dialysis patients with renal anemia (Hb ≤ 10.5 g/dl) received C.E.R.A. monthly from the start of therapy. The trial comprised a titration phase (Months 2 - 7) and an evaluation phase (Months 8 - 9). Mean Hb increased from 9.8 ± 0.7 g/dl at baseline to 11.5 ± 1.1 g/ dl during the evaluation phase (mean change 1.6 ± 1.1 g/dl; 95% CI 1.4 - 1.8 g/dl). Among patients with two Hb values available during the evaluation phase, 18.1% (19/105) were maintained at 11.0 - 12.0 g/dl and 49.5% (52/105) at 11.0 - 13.0 g/dl. 20 patients started dialysis and received C.E.R.A during the titration phase. Results: Their mean Hb increased from 10.6 ± 1.6 g/dl (last pre-dialysis value) to 11.3 ± 1.6 g/dl. Nine patients (4.9%) experienced one adverse event with a suspected relation to C.E.R.A.; 5 were graded serious. 54 patients (29.3%) discontinued the study (22 for adverse events). Conclusion: Although no control arm was included, such that robust comparisons cannot be drawn, these results suggest that C.E.R.A. therapy can be initiated once a month in non-dialysis CKD patients with renal anemia without appearing to compromise the rate or degree of Hb correction.
Michael Koch; Dirk Henrich; Justus Faust; Jan Nawka; Thomas Rath; Christoph Wanner
Related Documents :
1650667 - Bromovinyldeoxyuridine treatment of herpetic keratitis clinically resistant to other an...
2220727 - Duodenal ulcer hemorrhage with and without dyspepsia.
2129837 - Clinical and upper gastroendoscopic features of patients with dengue virus infection.
21098657 - Glycated haemoglobin and the incidence of end-stage renal disease in diabetics.
6476597 - Evaluation of a low-flow oxygen-conserving nasal cannula.
21253517 - Cardiovascular complications in ckd patients: role of oxidative stress.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Clinical nephrology     Volume:  78     ISSN:  0301-0430     ISO Abbreviation:  Clin. Nephrol.     Publication Date:  2012 Sep 
Date Detail:
Created Date:  2012-08-09     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0364441     Medline TA:  Clin Nephrol     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  189-97     Citation Subset:  IM    
Department of Nephrology, University of Würzburg, Würzburg, Center of Nephrology, Mettmann, Dialysezentrum, Saarlouis, KfH Nierenzentrum, Mainz, Nephrologische Gemeinschaftspraxis, Hoyerswerda, Westpfalz-Klinikum GmbH, Abteilung für Nephrologie und Transplantationsmedizin, Medizinische Klinik , Kaiserslautern, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Factors affecting response and tolerability to ferumoxytol in nondialysis chronic kidney disease pat...
Next Document:  Prevalence of chronic kidney disease and its risk factors among family practice patients in Lithuani...